{
    "title": "Pfizer to pay $11.6 bln for Biohaven to tap migraine market",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10801083/Pfizer-buy-Biohaven-Pharmaceutical-11-6-bln-deal.html",
    "date": "2022-05-10",
    "keywords": [
        "pfizer",
        "migraine",
        "deal",
        "class",
        "cgrp",
        "company",
        "co",
        "cash",
        "drugmaker",
        "acquisition",
        "share",
        "sector",
        "analyst",
        "erman",
        "inc",
        "tuesday",
        "bet",
        "ability",
        "topselling",
        "pill",
        "surge",
        "revenue",
        "end",
        "decade",
        "peak",
        "asset",
        "odt",
        "calcitonin",
        "development",
        "nurtec",
        "abbvie",
        "selling",
        "amgen",
        "deeply",
        "space",
        "market",
        "executive",
        "vlad",
        "breakthrough",
        "franchise",
        "portfolio",
        "business",
        "innovation",
        "office",
        "aamir",
        "malik",
        "conference",
        "call",
        "size",
        "force",
        "inhibitor",
        "premium",
        "closing",
        "price",
        "stake",
        "biohaven",
        "stock",
        "biotech",
        "value",
        "weight",
        "lack",
        "mampa",
        "news",
        "doctor",
        "sentiment",
        "sandler",
        "christopher",
        "purchase",
        "cancer",
        "medivation",
        "mohit",
        "bansal",
        "note",
        "balance",
        "sheet",
        "bengaluru",
        "editing",
        "koyyur",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}